HDAC9 and idiopathic pulmonary fibrosis: In summary, the potent anti-proliferative and anti-fibrotic properties of romidepsin in vitro and in vivo strongly support progression of this FDA-approved HDAC inhibitor towards a clinical trial to evaluate its potential as a new therapy for IPF.